Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-27

Study Completion Date

2022-07-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluate the percentage of women with thin endometrium who achieve an endometrial thickness equal to or greater than 7 mm after administration of PRGF (plasma rich in growth factors)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Platelet Rich Plasma for Insufficient Endometrium

NCT05538338

Infertility of Uterine Origin

RECRUITING NA

Autologous Platelet-Rich Plasma (PRP) and Endometrial Thickness

NCT03067623

Thin Endometrium Endometrial Disorder Endometrial Thickness Not Growing Under Estrogen Stimulation

UNKNOWN PHASE2

Hysteroscopic Injections of Autologous Endometrial Cells and Platelet-rich Plasma in Patients With Thin Endometrium

NCT05455151

Thin Endometrium

COMPLETED PHASE1

Autologous Platelet-rich Plasma for Clomiphene Citrate-induced Thin Endometrium

NCT03770026

Infertility, Female, Associated With Anovulation

COMPLETED PHASE2/PHASE3

Umbilical Cord Plasma for Treating Endometrial Pathologies (Thin Endometrium / Asherman's Syndrome/ Endometria Atrophy)

NCT05095597

Asherman Syndrome Endometrial Atrophy

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility Infertility, Female

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRGF

Plasma rich in growth factors (PRGF) administration

Group Type EXPERIMENTAL

Plasma rich in growth factors (PRGF-Endoret)

Intervention Type DRUG

Intrauterine administration of PRGF

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plasma rich in growth factors (PRGF-Endoret)

Intrauterine administration of PRGF

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women who signed informed consent.
* Women who understand the Spanish language.
* Women under 42 years

Exclusion Criteria

* Thrombopenia.
* Congenital or acquired uterine malformations that reduce embryo implantation or term gestation.
* Ovarian tumors.
* Benign uterine tumors require surgical treatment
* Local acute inflammatory diseases
* Patients with malignant tumors requiring chemotherapy.
* Patients with acute or chronic infectious or inflammatory diseases requiring active treatment with drugs that may interfere with implantation and gestation.
* Chronic treatment with NSAIDs (Nonsteroidal anti-inflammatory drugs)

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No